Ryan Merkow, MD, MS, and Louise Catherine Connell, MB BCh BAO, BMedSc, discuss the current treatment landscape in colorectal cancer liver metastases, highlighting unmet needs in the treatment space.
Pertuzumab Plus Trastuzumab Surpasses Prespecified Activity Threshold in ERBB2/3-Altered Biliary Tract Cancer
Merkow and Connell Highlight Considerations for HAI Pump Use in CRC
Relatlimab Plus Nivolumab/Chemo Misses ORR End Point in LAG-3+ Advanced Gastric/GEJ Cancer
FDA Approval Insights: Cilta-Cel in R/R Myeloma After at Least 1 Prior Line of Therapy
IBI343 Receives Breakthrough Therapy Designation in China for Claudin 18.2+ Advanced Gastric/GEJ Cancer
FDA Grants Orphan Drug Designation to 9MW2821 for Esophageal Cancer
Capivasertib/Fulvestrant Improves PFS2 in Pretreated PIK3CA/AKT1/PTEN+ HR+/HER2– Breast Cancer
T-DXd Maintains Survival Advantage Over Physician’s Choice of Therapy in HER2+ Metastatic Breast Cancer
Ipatasertib/Anti-HER2 Therapy Is Safe and Active in PIK3CA-Mutant, HER2+ Advanced Breast Cancer
Dato-DXd Reduces High-Grade TRAEs vs Chemo in Pretreated, HR+/HER2– Advanced Breast Cancer